Skip to main content

Advertisement

Table 1 Correlation between EILD and clinicopathological variables of the patients treated with eribulin

From: Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study

Variable   Number of cases (%)
   EILD
   Yes No P-value
  Total
  (n = 157) (n = 42) (n = 115)
Age (years)     
 Median (range) 56 (25 ~ 81 y) 57 (25–81 y) 52 (38–73 y) 0.37
PS     
 0 104 34 70 0.05
 1 41 7 34  
 2 12 1 11  
Comorbid disease     
 Yes 41 12 29 0.67
  Diabetes 7 4 3  
  Hypertension 22 9 13  
  Hyperlipidemia 6 1 5  
  Others 14 2 12  
 No 127 31 96  
History of other malignancy     
 Yes 4 0 4 0.57
 No 153 42 111  
Breast surgery     
 Yes 142 39 103 0.75
  Total mastectomy 101 25 76  
  Breast-conserving surgery 35 13 22  
  Bilateral surgery 6 1 5  
 No 15 3 12  
DFI (years)     
 Median (range) 2.8 (0 ~ 26.5) 3.3 (0–15.6) 2.6 (0–26.5) 0.24
BMI     
 Median (range) 22.2 (15.8 ~ 36.3) 24.5 (16.8 ~ 36.3) 21.5 (15.8 ~ 35.4) <0.0001
HR (ER/PgR) status     
 Negative 36 5 31 0.08
 Positive 121 37 84  
HER2 status     
 Negative 132 37 95 0.56
 Positive 25 5 20  
Previous chemotherapy (including adjuvant setting)     
 Anthracycline     
  Yes 146 40 106 0.73
  No 11 2 9  
 Taxane     
  Yes 149 39 110 0.44
  No 8 2 5  
 Capecitabine     
  Yes 108 25 83 0.13
  No 49 17 32  
Number of previous endocrine therapy for metastatic disease     
 0 65 14 51 0.37
 1 34 14 20  
 2 31 7 24  
 3 18 4 14  
 4 4 2 2  
 5 4 1 3  
 6 1 0 1  
Type of prior treatment     
 Chemotherapy 110 25 85 0.71
 Endocrine therapy 42 15 27  
 No 5 2 3  
Liver metastasis     
 Yes 77 23 54 0.39
 No 80 19 61  
Concurrent trastuzumab     
 Yes 13 3 10 0.99
 No 144 39 105  
Dose intensity of eribulin (mg/m2/week)     
 Median (range) 0.72 (0.30 ~ 0.91) 0.72 (0.30–0.90) 0.72 (0.32–0.91) 0.76
  1. Abbreviation: EILD eribulin-induced liver dysfunction, PS performance status, DFI disease free interval, BMI body mass index, HR hormone receptor, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor 2